Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications

Mainul Haque1, Santosh Kumar2, Jaykaran Charan3, Rohan Bhatt4, Salequl Islam5, Siddhartha Dutta2, Jha Pallavi Abhayanand2, Yesh Sharma6, Israel Sefah7,8, Amanj Kurdi9,10, Janney Wale11 and Brian Godman9,12,13,14 *

1Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, Malaysia, 2Department of Periodontology and Implantology, Karnavati University, Gandhinagar, India, 3Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India, 4Department of Pediatric Dentistry, Karnavati University, Gandhinagar, India, 5Department of Microbiology, Jahangirnagar University, Savar, Bangladesh, 6Department of Conservative Dentistry and Endodontics, Rajasthan University of Health Sciences, Jaipur, India, 7Pharmacy Department, Ghana Health Service, Keta Municipal Hospital, Keta-Dzelukope, Ghana, 8Pharmacy Practice Department, School of Pharmacy, University of Health and Allied Sciences, Volta Region, Ghana, 9Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom, 10Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq, 11Independent Consumer Advocate, Brunswick, VIC, Australia, 12Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden, 13School of Pharmacy, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa, 14School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia

Background: COVID-19 has already claimed a considerable number of lives worldwide. However, there are concerns with treatment recommendations given the extent of conflicting results with suggested treatments and misinformation, some of which has resulted in increased prices and shortages alongside increasing use and prices of personal protective equipment (PPE). This is a concern in countries such as India where there have been high patient co-payments and an appreciable number of families going into poverty when members become ill. However, balanced against pricing controls. Community pharmacists play a significant role in disease management in India, and this will remain. Consequently, there is a need to review prices and availability of pertinent medicines during the early stages of the COVID-19 pandemic in India to provide future direction.

Objective: Assess current utilisation and price changes as well as shortages of pertinent medicines and equipment during the early stages of the pandemic.

Our Approach: Multiple approach involving a review of treatments and ongoing activities across India to reduce the spread of the virus alongside questioning pharmacies in selected cities from early March to end May 2020.

Our Activities: 111 pharmacies took part, giving a response rate of 80%. Encouragingly, no change in utilisation of antimalarial medicines in 45% of pharmacies despite endorsements and for antibiotics in 57.7% of pharmacies, helped by increasing need for a prescription for dispensing. In addition, increased purchasing of PPE (over 98%). No
INTRODUCTION/BACKGROUND

Healthcare System in India and Role of Community Pharmacists

Until recently, healthcare in India has largely been funded through out-of-pocket payments, with payments relatively stagnant at between 69% to over 75% of total healthcare expenditure (Kastor and Mohanty, 2018; Selvaraj et al., 2018; Sood and Wagner, 2020). The cost of medicines accounted for an appreciable proportion of this at over 60% of total expenditure and over 70% of out-of-pocket expenditures (Selvaraj et al., 2018; Satheesh et al., 2019), which is similar to other lower- and middle-income countries (LMICs) (Cameron et al., 2009). These out-of-pocket expenses have potentially catastrophic consequences if family members become ill, exacerbated by an increase in non-communicable diseases (NCDs) in India in recent years. As a result, up to 39 million people are pushed into poverty each year in India due to healthcare payments (Garg and Karan, 2009; Kastor and Mohanty, 2018; Reddy, 2018; Selvaraj et al., 2018). This is beginning to change with ongoing reforms to provide health insurance coverage for up to 100 million families in poverty (Reddy, 2018; Sood and Wagner, 2020); however, this will take time in view of a number of challenges including patient enrollment, agreeing the future role of physicians, necessary strengthening of regulatory systems and increasing the percentage of gross domestic product (GDP) spent on health (Reddy, 2018; Editorial, 2019; Sood and Wagner, 2020). These reforms will also involve improving healthcare delivery in rural areas to address current inadequacies, for instance through the instigation of 150,000 health and wellness centers as healthcare facilities (Kasthuri, 2018; Sood and Wagner, 2020).

In view of the contribution of the costs of medicines to total healthcare costs in India, coupled with existing high co-payments for visiting physicians and funding medicines, community pharmacies have and will continue to play an appreciable role in managing patients in India (Abdulsalim et al., 2018; Daftary et al., 2019; Nafade et al., 2019; Abdulsalim et al., 2020; Sousa Pinto et al., 2020). Key reasons include avoiding paying physician fees, especially for milder symptoms, accessibility with long opening hours, and a lack of queues compared with ambulatory care clinics (Soumya et al., 2016; Mohathasim Billah and Venkatesan, 2017; Daftary et al., 2019). As a result, community pharmacists in India are the first point of healthcare professional contact for up to 40% of patients with tuberculosis (TB) symptoms and an appreciable number of patients continue to seek their advice after diagnosis (Daftary et al., 2019).

Overall, community pharmacists in India play a crucial role in optimizing the use of medicines and improving patient outcomes whilst seeking to prevent the misuse of medicines (Mohathasim Billah and Venkatesan, 2017; Abdulsalim et al., 2018). This is similar to their roles in other countries where they are often the first healthcare professional patients consult regarding their illness, and they are increasingly involved in the management of chronic and other diseases (Khanal et al., 2016; Markovic-Pekovic et al., 2017; Akutey et al., 2018; Sousa Pinto et al., 2020). The cost of medicines to patients in India have been helped in recent years by ongoing reforms since 2013 to fix prices for essential medicines as well as encourage the prescribing of generic medicines where possible (HealthWorld, 2016; BioVoice, 2018; Pavithra, 2019). However, concerns have been raised about the knowledge of pharmacists regarding pharmaceutical care, the actual extent of pharmaceutical care activities undertaken in practice, and the continued self-purchasing of antibiotics that exists despite legislation, which along with increased utilisation rates of antibiotics in recent years has led to increased antimicrobial resistance (AMR) (Satheesh et al., 2019; Nafade et al., 2019; Farooqui et al., 2018; pal Jeyamani et al., 2018).

Reforms are also needed in India regarding the management of NCDs, with NCDs now the leading cause of death in India. NCDs accounted for 60% of all deaths in India in 2014 alongside continued high rates of infectious diseases including TB and growing AMR rates (Farooqui et al., 2018; Kastor and Mohanty, 2018; Daftary et al., 2019). The growing burden of NCDs including cardiovascular disease (CVD), hypertension, and diabetes, coupled with the associated need for medicines, will appreciably increase healthcare costs unless addressed, alongside increasing expenditure on antimicrobials with increasing utilisation (Farooqui et al., 2018; India State-Level Disease Burden Initiative CVDC, 2018; India State-Level Disease Burden Initiative Diabetes C, 2018; Ramakrishnan et al., 2019; Vijayakumar et al., 2019).

It is likely therefore that any Government activities to transfer funds and personnel to tackle COVID-19 will impact on planned activities to reduce the growing burden of NCDs in India as well as...
as any planned activities surrounding other infectious diseases including reducing AMR rates. Consequently, existing healthcare needs and activities need careful monitoring to reduce the extent any unintended consequences arising from the pandemic.

**COVID-19 and Risk Factors**

COVID-19 was first identified in Wuhan in China in December 2019, quickly spreading to all continents (Kumar et al., 2020; Li et al., 2020; Wu and McGoogan, 2020). By September 27, 2020 there were 32.73 million cases with over 990,000 deaths worldwide, giving a case fatality ratio (CFR) among confirmed cases of 3.03% (WHO, 2020a). This included over 6.72 million confirmed cases in the WHO South East Asian Region including India, with over 110,000 deaths, giving a CFR of 1.65% (WHO, 2020a). It is recognised that there has been appreciable under-reporting of prevalence rates and deaths in a number of South East Asian countries with a lack of testing capabilities, particularly at the beginning (Anwar et al., 2020; Associated Press, 2020; Lee, 2020).

COVID-19 is transmitted from person to person principally through respiratory droplets and aerosol transmission, alongside direct contact with contaminated surfaces, forming the basis of preventative measures (Anderson et al., 2020; Haque, 2020; Klompas et al., 2020; Ng et al., 2020; Pradhan et al., 2020; WHO, 2020b; World Health Organisation, 2020). Increased morbidity and mortality from COVID-19 appears to be associated with a number of underlying health conditions including CVD, hypertension, diabetes, chronic obstructive pulmonary disease (COPD), shortness of breath, smoking and blood types (Aghagoli et al., 2020; Alqahtani et al., 2020; Ellinghaus et al., 2020; Huang et al., 2020; Richardson et al., 2020; Vardavas and Nikitara, 2020; Zhao et al., 2020; Zheng et al., 2020). Ethnicity may also be important with patients in the United Kingdom of Indian origin at appreciably increased risk of dying from COVID-19 vs. those of white ethnicity (Khunti et al., 2020; Kirby, 2020; Public Health England, 2020; Sonwalkar, 2020). Smoking is also an issue in India with high rates particularly among men (Mishra et al., 2016; Mohan et al., 2018; WHO, 2018); however, rates appear to be decreasing following the instigation of the WHO’s framework convention on tobacco control and other measures, which is encouraging (Suliankatchi Abdulkader et al., 2019).

**Response to COVID-19 and Concerns in India**

The first reported cases in India for COVID-19 were in Kerala, on January 30, 2020 (Kamath et al., 2020; Kumar et al., 2020; WHO India, 2020a). As of September 27, 2020, 5.992 million confirmed cases and over 94,000 deaths have been reported in India due to COVID-19, the highest rates in the WHO South East Asia region and giving a CFR of 1.58% (WHO, 2020a). This is likely to be an underestimate though with lack of testing and capacity issues certainly during the early stages of the pandemic until the number of testing facilities appreciably increased with the help of the private sector Box 1, exacerbated in some cases by patients having to cover the high costs of tests themselves although this is now changing (Alluri and Pathi, 2020; Associated Press, 2020). By late March, there were only 18 tests being undertaken per million population in India vs. 6,931 per million in South Korea (Kamath et al., 2020). By 25 April, over 5.79 million tests had been undertaken from data supplied by the Indian Council of Medical Research (ICMR) (Pai et al., 2020). Other reports suggest a cumulative total of 3.8 million tests by June 1, 2020 also citing ICMR. The testing rates at the end of May/beginning of June were still only 0.08 per 1,000 people in India vs. 1.02 in Italy and 1.16 in the USA (Yadav et al., 2020). Since then, with the help of an appreciable increase in the number of testing facilities and increased production of testing equipment (ICMR, 2020a; Yadav et al., 2020), the cumulative number of tests as of July 8, 2020 was over 110 million with 1,132 laboratories now involved with testing throughout India (ICMR, 2020b; ICMR, 2020c). ICMR has also recently approved the use of a point-of-care rapid antigen test to aid early detection of COVID-19 to further enhance the numbers tested to aid the “test-track-treat” strategy (Bhargava, 2020; ICMR, 2020d).

India faces ongoing challenges with preventing the spread of COVID-19, including issues with social distancing in big cities with crowded streets, lack of access to clean water, lack of regular hand washing facilities in an appreciable number of households, lack of physicians, lack of hospital beds (at 0.5 to 0.7 beds per 1,000 compared with 4.3 per 1,000 in China) and ICUs vs. higher income countries, just 20,000 ventilators in the country, and a lack of personal protective equipment (PPE) among healthcare professionals (Bhattacharya et al., 2020; Dutta, 2020; Ganapathy, 2020; Garattini et al., 2020; Kamath et al., 2020; Ma and Vervoort, 2020; Roy et al., 2020; Saalig, 2020).

There are also challenges with high co-payments for treating existing infectious and non-infectious diseases, which will be exacerbated by diverting expenditures towards prevention and management of COVID-19, as well as purchasing basic necessities if incomes are reduced as a result of the pandemic (Ganapathy, 2020; Kamath et al., 2020). This is in addition to concerns about the routine availability of medicines to treat priority diseases in India. Medicine prices are typically lower in India compared with a number of other LMICs although appreciable variation in prices has been seen among pharmacies (Millard et al., 2018; Babar et al., 2019; Ray et al., 2020). Having said this, as mentioned, there are ongoing activities by the Indian Government to regulate the prices of medicines in India to help with co-payments for essential medicines (HealthWorld, 2016; Pavithra, 2019). Purchasing personal protective equipment (PPE) remains an issue with the costs of the materials to make PPE appreciably increasing following the pandemic (Business Today, 2020); however, prices and shortages may be alleviated by increased local production along with pricing and manufacturing regulations (Bhattacharya et al., 2020; GMA Consulting Group, 2020; Pandey, 2020).

Ongoing national and regional activities during the early stages of the pandemic to help reduce the spread of COVID-19, as well as the financial consequences, are contained in Table 1. It was perceived that timely decisions to introduce lockdowns helped with controlling infection rates initially although at a negative socioeconomic cost (Pai et al., 2020). However, we are now seeing a spike in infection rates as lockdown measures are
BOX 1 | Testing capabilities and type in India (Yadav et al., 2020; ICMR, 2020c).
- Different methods are used to test for COVID-19. These include:
  - ICMR-validated RT-PCR (reverse transcription polymerase chain reaction test)
  - MolBio Diagnostics’ Truenat (completely indigenous diagnostic platform (ICMR, 2020a)
- Facilities for the various testing approaches as of 31 May 2020:
  - Real-time RT-PCR: 481 facilities - government: 313 and private: 168
  - Truenat test for COVID-19: 140 facilities - government: 131 and private: 9
  - CBNAAT for COVID-19: 55 facilities - government: 28 and private: 27
- Facilities for the various testing approaches as of 8 July 2020:
  - Real-time RT-PCR: 603 facilities - government: 373 and private: 230
  - Truenat test for COVID-19: 435 facilities - government: 400 and private: 35
  - CBNAAT for COVID-19: 94 facilities - government: 33 and private: 61

| TABLE 1 | Range of national and regional activities in India in 2020 from January 2020 up to June 2020 to help reduce the spread of COVID 19 and its impact. |
|---------------------------------|-------------------------------------------------------------------------------------------------|
| Activities                      | Details of activities including timelines during 2020 where documented                                                                         |
| Healthcare activities           | • January 30, 2020—Surveillance is being strengthened at points of entry into the country and in the community and the WHO issued advice to patients on hand sanitisation and other measures (WHO India, 2020a) |
|                                 | • February 6, 2020—The government issued travel restrictions to China and anyone with a travel history from China from January 15, 2020 will be quarantined (WHO India, 2020b). The WHO is also working with key government and other groups to offer support and help (WHO India, 2020b). During this period, the ministry of health instigated a 24 h/7 days-a-week disease alert hotline to provide information including clinical guidance (Kumar et al., 2020; Ministry of Health and Family Welfare Government of India, 2020), with the alcohol industry engaged in developing hand sanitisers and the textile industry producing PPE to address shortages (Bhattacharya et al., 2020). |
|                                 | • March 8, 2020—52 laboratories were identified by ICMR for undertaking testing for COVID-19 (WHO India, 2020c) (now expanded in Box 1). In addition, all international passengers irrespective of nationality are now mandated to undergo universal medical screening at airports with screening facilities in place at 30 airports and WHO India is supporting capacity building and training across India (WHO-HO India, 2020c). Those arriving from China, France, Germany, Italy, Iran, Republic of Korea, Spain and Germany after February 15, 2020 to be quarantined for a minimum of 14 days starting March 13, 2020 (WHO India, 2020d). |
|                                 | • March 15, 2020 - all movement suspended for foreigners through all immigration land check posts at Bangladesh, Nepal, Bhutan and Myanmar borders with only a few exceptions (Nepalese and bhutanesian nationals) |
|                                 | • March 22, 2020: “Janata curfew” introduced with 14 hour lockdown (Kumar et al., 2020). In addition, all train services suspended until 31 March, although goods trains may continue for essential commodities, and all children under 10 and all elderly over 65 to remain at home and avoid mass gatherings unless a medical reason or for essential services (WHO India, 2020e). |
|                                 | • Ministry of Pharma and Consumer Affairs instructed to take necessary action to regulate the price for PPE and other health related materials and to facilitate their availability in hospitals and to the population at large (WHO India, 2020a) |
|                                 | • WHO working with ICMR to enhance the testing strategy (WHO India, 2020a) (now appreciably expanded—Box 1), with ICMR issuing guidelines for the clinical management of patients with COVID-19. |
|                                 | • March 25, 2020—Further lockdown measures initiated for 21 days starting on 25 March (Kumar et al., 2020; PIBG, 2020), and extended to 3 May (Kumar et al., 2020). |
|                                 | • India introduced an export ban on hydroxychloroquine but later rescinded as seen in for instance Malaysia (Duffy & Hussain, 2020; Sibbal, 2020) |
|                                 | • April 2020—ICMR issued national guidelines for ethics committees reviewing biomedical and health research during the COVID-19 pandemic (Indian Council of Medical Research, 2020). |
|                                 | • April 14, 2020—Lockdown extended until May 3, 2020 (Prime Minister’s Office, 2020) |
|                                 | • May 1, 2020—Further lockdown extended for 2 weeks from May 4, 2020; however, variable activities across districts depending on current infection rates (Ministry of Home Affairs India, 2020a) |
|                                 | • June 1, 2020—Still strict enforcement of lockdown in containment zones with re-opening of activities outside of containment zones (Ministry of Home Affairs India, 2020b). |
|                                 | • 28 June—Indian railways will not resume a regular service until at least 12 August due to a spike in cases (Associated Press, 2020) |
|                                 | • The government in India announced US $2.1 billion aid to help the health sector fight the pandemic (Pa et al., 2020) |
|                                 | • March 27, 2020—Government announces a $22.6 billion stimulus package to aid poorer communities affected by lockdown measures (Ahmed, 2020). |
|                                 | • End March 2020—Interest rates reduced, Tata group has donated approximately $200 million and the Aditya Birla group approximately $70 million to fight the spread of the pandemic and provide medical supplies (Gandhi 2020). |
|                                 | • May 13, 2020—Prime minister promises a $266 billion package to protect the economy from Covid-19 (Gupta & Sud, 2020) |

relaxed despite warnings to maintain social distancing and as a consequence of the recent monsoons (Associated Press, 2020; Siddiqui, 2020). Consequently, there has been a re-instigation of such measures although rail and other services have resumed and places of worship have opened (ANI, 2020; The Hindu, 2020).

Currently, there is not a cure for COVID-19; however, a number of medicines have been proposed and are undergoing trials (Sanders et al., 2020; Scavone et al., 2020). Recently, dexamethasone has been shown in the UK Recovery Trials to reduce deaths in ventilated patients and in those receiving oxygen only (Horby et al., 2020a). Remdesivir has shown encouraging results in one study after earlier concerns over an underpowered study (Beigel et al., 2020; ECDC, 2020; Wang et al., 2020). However a recent study among moderate patients failed to show similar benefit with remdesivir; consequently, still being considered as
experimental (Dyer, 2020; McCreary and Angus, 2020; Spinner et al., 2020). Triple antiviral therapy is also showing promise in the management of COVID-19 patients although numbers are small (Hung et al., 2020); however, more studies are needed before any recommendations can be made. In addition, an appreciable number of vaccines are now in development (Checchucci et al., 2020; ECDC, 2020).

However, there is still considerable controversy surrounding the use of chloroquine and hydroxychloroquine with or without azithromycin for both prevention and treatment of COVID-19, following initial studies in China (Boulware et al., 2020; Cortegiani et al., 2020; Gao et al., 2020; Gautret et al., 2020). Internationally, concerns were raised about the lack of comparisons in the initial studies as well as potential harm including cardiac side-effects (Abena et al., 2020; Borba et al., 2020; Gautret et al., 2020; International Society of Antimicrobial Chemotherapy, 2020; ISAC/Elsevier, 2020; Ferner & Aronson, 2020; Littlejohn, 2020). Subsequent studies, including registry studies, have enhanced these concerns for hydroxychloroquine for both the prevention and treatment of COVID-19 (Boulware et al., 2020; Das et al., 2020; Geleris et al., 2020; Horby et al., 2020b; Littlejohn, 2020; Rosenberg et al., 2020). Consequently, the European Medicines Agency has advised against its prescribing outside of clinical trials (European Medicine Agency, 2020) and Das et al. (2020) in India also advised caution (Das et al., 2020). The study by Mehra et al. (2020) also showed increased mortality with chloroquine or hydroxychloroquine; however, this paper has now been retracted and is currently subject to external auditing (Editorial, 2020; Mehra et al., 2020a; Mehra et al., 2020b). In view of recent studies including the UK Recovery trial, the WHO has now halted the hydroxychloroquine arm in the ongoing Solidarity Trial and the National Institute of Health in the US has also halted the use of hydroxychloroquine in its studies (ECDC, 2020; Horby et al., 2020b; NIH, 2020; WHO, 2020c).

Having said this, the ICMR under the Ministry of Health and Family Welfare in India continues to recommend hydroxychloroquine for prophylaxis despite potential concerns (Kumar et al., 2020; Natnayas et al., 2020; Pulla, 2020; Rathi et al., 2020; Tilangi et al., 2020). In a recently published case controlled study, Chatterjee et al. (2020) demonstrated that the prescribing of four or more maintenance doses of hydroxychloroquine was associated with a significant reduction in the odds of healthcare workers getting COVID-19 (Chatterjee et al., 2020). Other treatments initially recommended by ICMR and others include lopinavir-ritonavir, although there is contrasting data regarding its effectiveness in COVID-19 patients (Bhatnagar et al., 2020; Cao et al., 2020; Kumar et al., 2020). More recently, the WHO has discontinued the lopinavir-ritonavir arm of the Solidarity trial with the interim results showing this combination demonstrated little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care (WHO, 2020c). Overall, further studies are needed before specific treatments can be robustly recommended given the continuing concerns with a number of treatments, the redaction of recent studies and issues with study design and setting (Bae et al., 2020; Godman, 2020; International Society of Antimicrobial Chemotherapy, 2020; Mehra et al., 2020b).

We are aware the endorsement of hydroxychloroquine has resulted in appreciably increased use in a number countries and localities along with increased prices, although there have been hospitalisations and deaths from poisoning (Abena et al., 2020; Buasi and Adebayo, 2020; Haque et al., 2020; Kwasi, 2020; Mendel et al., 2020; Salo, 2020; Topp, 2020; Vaduganathan et al., 2020). Increased prices can be a concern in India with potentially detrimental consequences for families if limited available funds for priority disease areas including NCDs are being diverted towards purchasing treatments where there are ongoing controversy along with purchasing of PPE at increased prices (Business Today, 2020).

**Study Aims and Objectives**

In view of the current situation in India, we believed there was an urgent need to assess the impact of COVID-19 on the availability and prices of medicines and other technologies to prevent and treat COVID-19 in community pharmacies. The key considerations are the high rates of both infectious and non-infectious diseases in India, issues with sanitation and crowded streets, the catastrophic consequences for families when members become ill, and fears regarding the availability of regular medicines during the pandemic (Kastor & Mohanty, 2018; Selvaraj et al., 2018; Statista, 2020). Community pharmacists are a particular target since they currently play a key role in the management of diseases in India, with ongoing issues with access to physicians and high co-payments especially in rural areas (Abdulsalim et al., 2018; Daftary et al., 2019; Nafade et al., 2019). They are also in a good position to suggest to patients with more severe symptoms that they seek additional help (Amarilies et al., 2020). This is important since it is known it can be difficult to differentiate respiratory tract infections from COVID-19 in patients presenting with coughs and fever (Ongole et al., 2020).

We have seen prices rise for essential medicines in LMICs over time and for treatments for COVID-19, as well as appreciable price increases for the materials to make PPE in India following the start of the pandemic. In view of this, we believe it is important to evaluate the current situation in India regarding pertinent medicines and PPE to provide future guidance at this critical time (Kasorde et al., 2019; Buasi & Adebayo, 2020; Business Today, 2020). Consequently, we sought to address this through direct contact with community pharmacists across India. However, we are aware of government regulations regarding the pricing of essential medicines in India (HealthWorld, 2016; Pavithra, 2019). As a result, in this initial study we sought to assess the utilisation, availability and price changes of medicines and PPE for COVID-19 among a number of cities across India to provide future direction to key stakeholder groups in India. Senior level co-authors would also be targeted to provide guidance based on their experiences across LMICs.

We have not assessed the influence of the various Government initiatives (Table 1) on the prevalence and mortality of COVID-19 in India. We are aware of the concerns about the testing rates for COVID-19 certainly initially as well as evolving strategies to address ongoing spikes in infection rates as lockdown measures are eased and with the advent of the monsoons (Associated Press, 2020; Siddiqui, 2020). We will though be monitoring morbidity and mortality rates alongside the unintended consequences of lockdown and other measures given rising prevalence rates of...
COVID-19 in India and existing high prevalence rates for both infectious and non-infectious diseases, and will be reporting on this in future studies. Unintended consequences include issues of increased gender violence as well as mental health issues associated with any stigma with COVID-19 as well as lockdown measures (IFRC & WHO, 2020; Rajkumar, 2020; SADC, 2020). In addition, rising rates of NCDs especially if patients cannot attend clinics or receive their medicines due to lockdown measures as well as having affordability issues with medicines through lack of earnings due to lockdown and other measures (Basu, 2020; Kluge et al., 2020).

**METHODOLOGY**

We initially undertook a narrative review of the current situation regarding COVID-19 in India and on suggested treatments. We subsequently undertook quantitative research in the form of a survey. The narrative review included a review of current and proposed treatment approaches including vaccines and recommendations for preventing and managing COVID-19, including the role of community pharmacists as well as issues of misinformation. We did not systematically review the papers or other information sources for their quality using well-known scales such as the Newcastle-Ottawa scale as some of the papers quoted are in pre-publication format and we have used a considerable number of internet sources (Almeida et al., 2018). However, the publications and internet sources were filtered by the co-authors to add robustness to the paper and its suggestions.

The information sourced from the pragmatic review of the literature was combined with a questionnaire survey among community pharmacies (Appendix 1) to assess the situation regarding prices, availability and usage patterns of carefully selected medicines that could potentially be used in the management of COVID-19, as well as PPE, soon after the start of the pandemic.

For this rapid analysis, we selected via purposive sampling representation of pharmacies from across India. This included Ahmedabad, Jodhpur, and Pune as part of Western India, West Singhbhum and Kolkata as part of Eastern India, and Delhi in northern India. Convenience sampling in these cities was used to select pharmacists through emails, telephone contact, personal contacts and other mechanisms. There was no sample size calculation as there was no previous data in India to base calculations upon. However, the intention was to undertake the research among an appreciable number of community pharmacies across India to gain good insights and provide a basis for future studies if needed.

Key questions were to assess patterns of demand, availability, and price changes of selected medicines and equipment, as well as the potential future role of pharmacists to reduce misinformation. These are contained in Box 2 (building on Appendix 1). Those conducting the research were provided with an Excel spreadsheet of the questions to complete. The questions were open ended as we were aware that in a number of situations we would be unable to obtain exact details of changes in utilisation patterns and prices; however, we wanted to capture data including more general information for this initial study. The answers were collated where possible into logical bands for comparisons with other countries such as Bangladesh (Haque et al., 2020). These bands were not pre-defined as this was an exploratory rapid pilot study, with changes in prices based on local prices. In addition, general information would be sufficient if the pharmacists were unable to be specific given the exploratory nature of this study.

The pharmacists were briefed on the objectives of the study with the option to participate or not, with confidentiality maintained throughout. Our hypothesis, based on findings in other countries, was that there would be shortages of some of the medicines, although countered in India as a chief producer of medicines with export bans in place certainly initially (Duffy & Hussain, 2020) Price rises especially for medicines potentially tempered though by the Ministry of Pharma and Consumer Affairs being instructed to take necessary action to regulate these for PPE and other health related materials alongside existing regulations for (Table 1) (WHO India, 2020e). The findings were compiled into a tabular format. No formal statistical analysis was performed as the level of detail varied considerably across the pharmacies.

**TABLE 2 | Details of responses among pharmacy/drugs stores approached.**

| Group 1 | Group 2 | Total (total and %) |
|---------|---------|---------------------|
| How many pharmacies approached (in number) | 69 | 66 | 135 |
| How many accepted to take part (in number) | 56 | 55 | 111 (82%) |
| How many refused (in number) | 13 | 11 | 24 (18%) |

NB—Groups 1 and 2 refer to the consolidation co-ordination of the findings by the principal co-author involved. The pharmacies were located throughout India (Figure 1, Table 3).
We subsequently combined the data collected using the experience of the co-authors regarding key issues including pharmaceutical care, health policy and self-purchasing in LMICs to provide future direction, building on comments from the interviewed pharmacists. We have previously successfully used this approach to provide future direction in LMICs (Godman et al., 2018; Godman et al., 2019a; Godman et al., 2020a; Godman et al., 2020b; Godman et al., 2020c; Godman et al., 2020d).

Ethical approval for this study was not required according to national legislation and institutional guidelines. However, all pharmacists freely provided the requested information having been given the opportunity to refuse to participate if wished. This is in line with previous studies undertaken by the co-authors in related areas including analysis of policies to enhance the rationale use of medicines and biosimilars, pricing policies and issues surrounding generics, which involved direct contact with health authority personnel and other key stakeholders (Moorkens et al., 2017; Godman et al., 2019b; Gad et al., 2020; Godman et al., 2020a; Godman et al., 2020c; Miljković et al., 2020).

RESULTS

Overall, 135 pharmacies were visited to give a response rate of 82% (Table 2).

We first report on changes in utilisation patterns before reporting on any price changes seen with the various medicines
and equipment as well as any shortages. The reported figures are absolute figures based on interviewee feedback.

**Utilisation**
Table 4 depicts changes in utilisation patterns for the various medicines, vitamins and PPE equipment and hand sanitisers from the beginning of March until the end of May 2020. Encouragingly, no change or decreased utilisation of antimalarials was seen in 45% of pharmacies taking part, with similarly limited increases in the utilisation of antibiotics (42.3% of pharmacies taking part). An appreciable increase in antibiotic utilisation was seen though in a small number of pharmacies.

Encouragingly, there was an increase in the purchasing of PPE and vitamins to boost the immune system in over 90% of pharmacies taking part, nearing 100% for PPE. It is likely that we will continue to see such increases in the purchasing of both of these if COVID-19 infection rates continue to increase following any easing of lockdown measures.

**Price Changes**
Table 5 depicts price changes for pertinent medicines and PPE. Encouragingly, there were limited price changes for antimalarials (only 16.2% of the pharmacies) and antibiotics (8.1% of the pharmacies). Contrasting with this, price increases were seen for PPE among over 90% of the pharmacies taking part in the study. This was only a slight increase, or an increase in only one of the three months, in 39.6% of pharmacies taking part.

**Medicine and Prevention Shortages**
Perhaps not surprisingly, shortages of some medicines and PPE were seen among the pharmacies in India (Table 6). These were principally confined to antimalarial medicines (70.3%) and PPE (88.3%).

**Potential Ways Forward to Address Misinformation and Enhance Appropriate Use of Medicines and Equipment Across Sectors**
Possible strategies based on interviewee and co-author feedback to address misinformation and other concerns regarding the management of COVID-19 and any unintended consequences are included in Table 7. We believe this is especially important for patients with NCDs given rising rates in India, and we will be researching this further.

**DISCUSSION**
We believe this is one of the first comprehensive studies worldwide to assess the impact of COVID-19 on the utilisation, availability and price changes of pertinent medicines and PPE used to prevent and treat COVID-19 among LMICs with a high response rate (82%) among those taking part. In India, high patient co-payments have contributed to potentially catastrophic consequences for families when members become ill, although this is beginning to change helped by ongoing legislation to moderate prices of essential medicines (Kastor and Mohanty, 2018; Reddy, 2018; Pavithra, 2019; Sood and Wagner, 2020).

As expected, our study demonstrates an increase in the utilisation of a number of suggested medicines and PPE, enhanced by endorsement of certain approaches including increased protection with PPE (Table 4). However, increases in utilisation were not as great for antimalarial treatments (55% of pharmacies noting an increase) and antibiotics (42.3% of pharmacies noting an increase) compared with analgesics (67.6%) and vitamins (90.1%). This is in line initiatives by the government advising pharmacists not to sell antimalarials and antibiotics without a prescription. The utilisation patterns seen in India appear similar to the situation in Bangladesh with antimalarial tablets (48.8% of pharmacies and drug stores seeing an increase), analgesics (97.6% of pharmacies and drug stores seeing an increase) and vitamins (90.6% seeing an increase), but lower than in Bangladesh with respect to antibiotics (with 70.6% of stores noting an increase), perhaps reflecting greater scrutiny over the need for patients to have a prescription for an antibiotic in India (Haque et al., 2020).

Price increases were also seen for pertinent medicines (Table 5), which was expected given some of the shortages seen (Table 6). However, price increases appeared appreciably lower than seen in Bangladesh with only 16.2% of pharmacies in India reporting a price increase for antimalarials vs. 50% in Bangladesh and only 8.1% of pharmacies in India reporting price increases for antibiotics vs. 34.7% in Bangladesh (Haque et al., 2020). We believe this reflects greater price controls for medicines in India compared with Bangladesh, providing direction to countries such as Bangladesh during the current pandemic and after (HealthWorld, 2016; Pavithra, 2019). A lower number of pharmacies in India (23.4%) also reported price increases for analgesics vs. 45.3% in Bangladesh (Haque et al., 2020). This may reflect greater production of ingredients for medicines (API) in India than seen in Bangladesh coupled with Government price controls (Pavithra, 2019). However, further research will be needed before any definitive statement can be made especially as shortages of antimalarials were seen in India during the study period (70.3% of pharmacies), although this was only short term in a third of these (Table 6). Shortages of antimalarial medicines were seen in 54.1% of pharmacies and drug stores in Bangladesh during the same period (Haque et al., 2020).

**TABLE 3 | Community Pharmacy location in India.**

| Location and State               | Number of pharmacies where data was collected |
|----------------------------------|-----------------------------------------------|
| JODHPUR, Rajasthan               | 44                                            |
| Jharkhand                        | 12                                            |
| Delhi, union territory           | 15                                            |
| Ahmedabad, Gujarat               | 15                                            |
| Kolkata, West Bengal             | 15                                            |
| Pune, Maharashtra                | 10                                            |
| Total                            | 111                                           |
As mentioned, we observed an appreciable increase in the use of PPE in both Bangladesh (over 95% of pharmacies and drug stores respectively) and India (98.2% respectively) during the study period (Haque et al., 2020). This was typically accompanied by shortages and price rises in both countries, some of which were substantial (Haque et al., 2020). We have also seen substantial increase in the price of PPE in other LMICs as the pandemic progresses (Weston, 2020).

Table 7 highlights potential activities that can be undertaken by key stakeholder groups in India and more widely to address issues and concerns with COVID-19. This includes addressing the unintended consequences of COVID-19 including issues of stigma as well as addressing concerns with appropriate identification and management of other infectious diseases apart from COVID-19 as well as among patients with chronic NCDs given rising rates of CVD and diabetes in India. We will be monitoring the situation with respect to hydroxychloroquine given ongoing controversies across countries.

We are aware of a number of limitations with this study. These include the fact that we were unable to obtain exact

| TABLE 4 | Utilisation changes for medicines and PPE between beginning March 2020 and end May 2020 among 111 pharmacies in India. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Antimalarials | Antibiotics | Analgesics | Vitamins/immune boosters | Face masks/PPE |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Decrease (including due to prescription required and no prescription) | 25 | 23 | 21 | 1 | 0 |
| No change | 25 | 41 | 15 | 10 | 2 |
| Slight increase | 10 | 5 | 1 | 2 | 0 |
| Increase (not specified) | 49 | 30 | 62 | 79 | 54 |
| 1.5 to 2 fold increase | 1 | 3 | 0 | 2 | 0 |
| 2 to 3 fold increase | 0 | 2 | 3 | 9 | 3 |
| 4 to 5 fold increase | 1 | 1 | 6 | 0 | 3 |
| Over 5 fold increase | 0 | 6 | 3 | 8 | 49 |
| Total | 111 | 111 | 111 | 111 | 111 |
| No change/decrease | 50 | 64 | 36 | 11 | 2 |
| % of the total | 45.0 | 57.7 | 32.4 | 9.9 | 1.8 |
| Increase % | 55.0 | 42.3 | 67.6 | 90.1 | 98.2 |

NB: No change also includes situations where not dispensed without a prescription (antimalarials and antibiotics).

| TABLE 5 | Price changes for medicines and PPE between beginning March 2020 and end May 2020 among 111 pharmacies in India. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Antimalarials | Antibiotics | Analgesics | Vitamins/immune boosters | Face masks/PPE |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Decrease | 0 | 0 | 1 | 0 | 0 |
| No change | 93 | 102 | 84 | 51 | 10 |
| Slight increase (including only one month out of the 3) | 10 | 2 | 2 | 2 | 44 |
| Increase (not specified) | 2 | 3 | 19 | 49 | 52 |
| Up to 2 fold | 0 | 0 | 0 | 0 | 0 |
| 2 to 3 fold increase | 1 | 4 | 4 | 4 | 1 |
| 3 to 4 fold increase | 0 | 0 | 1 | 2 | 1 |
| 4 to 5 fold increase | 2 | 0 | 0 | 3 | 2 |
| Over 5 fold increase | 3 | 0 | 0 | 0 | 1 |
| Total | 111 | 111 | 111 | 111 | 111 |
| No change/decrease | 93 | 102 | 85 | 51 | 10 |
| % of the total | 83.8 | 91.9 | 76.6 | 45.9 | 9.0 |
| Increase % | 16.2 | 8.1 | 23.4 | 54.1 | 91.0 |

| TABLE 6 | Shortages for medicines and PPE between beginning March 2020 and end May 2020 among 111 pharmacies in India. |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Antimalarials | Antibiotics | Analgesics | Vitamins/immune boosters | Face masks/PPE |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| No change/available | 33 | 100 | 109 | 84 | 13 |
| Part shortages (1-2 months) | 25 | 9 | 10 | 2 | 43 |
| Shortages (unspecified) | 53 | 2 | 2 | 2 | 55 |
| Total | 111 | 111 | 111 | 111 | 111 |
| No change % of total | 29.7 | 90.1 | 98.2 | 75.7 | 11.7 |
| Shortages % | 70.3 | 9.9 | 1.8 | 24.3 | 88.3 |
We also did not ask about shortages of other medicines such as those to treat patients with NCDs. Alongside this, we are aware that some of the shortages initially may have been due to transport and logistic issues. A number of these issues will be

---

**TABLE 7 | Key activities among stakeholder groups to improve prevention and management of patients with COVID-19.**

| Stakeholder group                  | Suggested activities                                                                 |
|------------------------------------|-------------------------------------------------------------------------------------|
| **Government**                     | • Encourage an evidence-based environment for key recommendations and pronouncements especially when proposing activities to prevent and treat COVID-19. This is particularly important given the controversies that continue to surround hydroxychloroquine and family resources spent on recommended treatments for the management of COVID-19 will mean less monies for other medicines and food especially among patients with existing diseases including chronic NCDs (India State-Level Disease Burden Initiative Diabetes C, 2018; Ramakrishnan et al., 2019). This is in line with advice and recommendations from the council for international organisations of medical sciences (Council for International Organizations of Medical Sciences, 2020)
• Ensure that there is active dissemination of suggested activities to prevent the spread of COVID-19 including sanitation in social media and other platforms given the increasing impact of social media in LMICs (Soon, 2020); however, mindful of the likely situation regarding concerns with social distancing and lack of clean water in many households
• Keep track of misinformation and any false claims for medicines or technologies for the diagnosis and management of COVID-19 given ongoing controversies regarding some recommended treatments and the financial consequences involved if scarce resources are diverted to purchase these products
• Ensure swift and strict action against fraudulent advertisements and sale of unproven products in this time of emergency building on activities in other countries (Davis, 2020; Dzurue, 2020)
• Continue with planned programmes to improve the management of patients with chronic NCDs, reduce AMR and actively treat infectious diseases to minimise the unintended consequences of COVID-19
• Continue to enhance local production of PPE where pertinent to address current shortages as well as seek mechanisms to keep any prices rises to a minimum (Bhattacharya et al., 2020; Pandey, 2020)
• Continue to adopt a phased approach to the easing of lockdown measures, with rapid re-introduction if needed (Habersaat et al., 2020)
| **Physicians**                     | • Enhance a philosophy of evidence-based medicine starting in medical school and continuing post qualification building on guideline initiatives in India (Mehndiratta et al., 2017), given current controversies surrounding hydroxychloroquine, lopinavir- ritonavir and remdesivir
• As part of this, continue to ensure prescribed/recommended treatments are evidence based through postgraduate training and other continuous professional development activities post qualification
• Continue to encourage where possible appropriate management of chronic NCDs including adherence to prescribed medicines given rising rates of NCDs in India
• Continue to encourage, where possible, the adoption of recommended strategies to prevent the spread of COVID-19 including pertinent PPE. This includes hand sanitisation as well as appropriate wearing of face masks
• Try to ensure that PPE and medicines, or suitable alternatives, helpful for patients with COVID-19 are routinely available, and help ensure where possible that any price rises are kept to a minimum given the number of people in India going into poverty when family members become ill—helped by current legislation regarding price rises especially for essential medicines coupled with ongoing programmes promoting generics (HealthWorld, 2016; Pavithra, 2019)
• Continue to argue against the need for antibiotics where this is a concern - helped recently by increasing recognition of the need for a prescription before dispensing (similar to antimalarial medicines)
• Work with patients to enhance good adherence to purchased medicines including those for NCDs and encourage appropriate referrals to other professionals where pertinent especially for moderate to severe disease
• Potentially become involved in vaccination programmes where there is unmet need as published studies suggest that when pharmacists provide immunizations they substantially increase the number of vaccinated people which is important at this time (Ögunleye et al., 2020)
| **Pharmacists**                    | • Where possible, engage with social media and channels to help promote evidence-based approaches to the prevention and management of COVID-19 given the level of misinformation seen to date—ensure messages are as clear as possible and in a positive language (Habersaat et al., 2020)
• Monitor the spread of misinformation regarding the treatment of COVID-19 with fake or unproven medical products and procedures that claim to diagnose, prevent or cure COVID-19, and work with governments and other key stakeholder groups to minimise their impact (Habersaat et al., 2020)
• Work with governments and other bodies to minimise the potential consequences of COVID-19 on mental health issues for healthcare professionals and patients
• Work with patients and groups to reduce concerns with stigma and reassure COVID-19 patients that they should pose no threat to the community after treatment and continue with their lives
• Seek to educate patients/build on current programmes regarding self-management in patients with chronic NCDs including the priority for medication adherence given lockdown restrictions
• Help explore new technologies with key stakeholders including the growing use of telemedicine approaches and other approaches to reduce the reliance on clinic attendance to manage NCDs
| **Patients/Patient organisations** | • Where possible, engage with social media and channels to help promote evidence-based approaches to the prevention and management of COVID-19 given the level of misinformation seen to date—ensure messages are as clear as possible and in a positive language (Habersaat et al., 2020)
• Monitor the spread of misinformation regarding the treatment of COVID-19 with fake or unproven medical products and procedures that claim to diagnose, prevent or cure COVID-19, and work with governments and other key stakeholder groups to minimise their impact (Habersaat et al., 2020)
• Work with governments and other bodies to minimise the potential consequences of COVID-19 on mental health issues for healthcare professionals and patients
• Work with patients and groups to reduce concerns with stigma and reassure COVID-19 patients that they should pose no threat to the community after treatment and continue with their lives
• Seek to educate patients/build on current programmes regarding self-management in patients with chronic NCDs including the priority for medication adherence given lockdown restrictions
• Help explore new technologies with key stakeholders including the growing use of telemedicine approaches and other approaches to reduce the reliance on clinic attendance to manage NCDs

NB: LMICs, low- and middle-income countries; NCDs, non-communicable diseases; PPE, personal protective equipment.
addressed in future studies. However, we are confident our findings can be helpful for future planning purposes in India and wider given the number of community pharmacies that were involved.

CONCLUSION

In our study we have seen increases in utilisation and prices as well as shortages of pertinent medicines and PPE used to prevent and treat COVID-19 in India. Encouragingly, the extent of shortages and price increases in India were not as high as originally expected, potentially helped by local production of medicines, including the active ingredients, greater scrutiny over the dispensing of antimalarials and antibiotics without a prescription, as well as government control over prices including recently; with similarities with Bangladesh. There are ongoing concerns and challenges regarding potential treatments including antimalarials, which needs urgent addressing. Increasing recognition of the need for evidence-based medicine in terms of treatment recommendations and prescribing can help further reduce inappropriate treatments being recommended, prescribed or dispensed. Patient organisations can also play a role through social media and other platforms to reduce the extent of misinformation and its potential damaging consequences. We will be monitoring this in the future.

REFERENCES

Abdulsalim, S., Unnikrishnan, M. K., Manu, M. K., Alrasheed, A. A., Godman, B., and Morisky, D. E. (2018). Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study. Res. Soc. Adm. Pharm. 14 (10), 909–914. doi:10.1016/j.sapharm.2017.10.008

Abdulsalim, S., Unnikrishnan, M. K., Manu, M. K., Alsaahali, S., Alrasheed, A. A., Martin, A. P., et al. (2020). Impact of a clinical pharmacist intervention on medicine costs in patients with chronic obstructive pulmonary disease in India. Pharmacocecon Open 4 (2):331–342. doi:10.1007/s41669-019-0172-x

Abena, P. M., Decloedt, E. H., Bottieu, E., Suleman, F., Adejumo, P., Sam-Agudu, N. A., et al. (2020). Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings. Am. J. Trop. Med. Hyg. 102 (6), 1184–1188. doi:10.4269/ajtmh.20-0290

Aghaoglu, G., Gallo Marin, B., Soliman, L. B., and Sellke, F. W. (2020). Cardio involvement in COVID-19 patients: risk factors, predictors, and complications: a review. J. Card. Surg. 35 (6), 1302–1305. doi:10.1111/jocs.14538

Ahmed, A. (2020). India outlines $23 billion stimulus to help poor hit by lockdown. Available at URL: https://www.weforum.org/agenda/2020/03/india-stimulus-support-lockdown-pandemic-covid19-economic-jobs/ (Accessed March 13 2013).

Akutey, R., Der, R., Owusu-Daaku, F., and Baiden, F. (2018). Using community pharmacies to expand access to screening for noncommunicable diseases in suburban Ghana-A facility-based survey on client needs and acceptability. Health Sci Rep. 1 (9), e79. doi:10.1002/hsr2.79

Alluri, A., and Pathi, K. (2020). India coronavirus: should people pay for their own Covid-19 tests? Available at URL: https://www.bbc.co.uk/news/world/asia-india-52322559 (Accessed April 20 2020).

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

AUTHOR CONTRIBUTIONS

All authors contributed to the study. MH, IS, AK and BBG designed the questionnaire with MH, SK, JC, RB, SI, SD, JPA, and YS. BBG developed the initial draft manuscript with all authors helping to refine the paper in successive drafts before submission.

ACKNOWLEDGEMENTS

We thank Nor Azlina A. Rahman for helpful comments regarding the sample and size of the study. We would like to acknowledge ‘mapchart.net’ to prepare a map diagram for our study, a free service.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.582154/full#supplementary-material.

Almeida, P. H. R. F., Silva, T. B. C., de Assis Acurcio, F., Guerra Júnior, A. A., Araújo, V. E., Diniz, L. M., et al. (2018). Quality of life of patients with type 1 diabetes mellitus using insulin analog glargine compared with NPH insulin: a systematic review and policy implications. Patient 11 (4), 377–389. doi:10.1007/s40271-017-0291-3

Alqahtani, J. S., Oyelade, T., Aldhahir, A. M., Alghandi, S. M., Almehmadi, M., Alqahtani, A. S., et al. (2020). Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 15 (5), e0233147. doi:10.1371/journal.pone.0233147

Amariles, P., Ledezma-Morales, M., Salazar-Ospina, A., and Hincapié-Garcia, J. A. (2020). How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal. Res Social Adm Pharm. 51551 (20), 30248. doi:10.1016/j.sapharm.2020.03.007

Anderson, E. L., Turnham, P., Griffin, J. R., and Clarke, C. C. Consideration of the aerosol transmission for COVID-19 and public health (2020). Risk Anal. 40 (5), 902–907. doi:10.1111/risa.13500

ANI (2020). COVID-19 measures extended till Sept 20 in WB. Availble at: https://www.aninews.in/news/national/general-news/covid-19-measures-extended-till-sept-20-in-wb-complete-lockdown-on-sept-7-11-20200826223016/ (Accessed September 26 2020).

Anwar, S., Nasrullah, M., and Hosen, M. J. (2020). COVID-19 and Bangladesh: challenges and how to address them. Frontiers. Public Health 8 (154). doi:10.3389/fpubh.2020.00154

Associated Press (2020). Asia Today: India’s cases spike again to near half-million. Available at URL: https://www.msn.com/en-gb/news/world/asia-today-india-s-cases-spike-again-to-near-half-million/ar-BR15YLe3ycod=spartandh-feeding (Accessed June 26 2020).

Babar, Z. U., Ramzan, S., El-Dahiyat, F., Tachmazidis, I., Adebisi, A., and Hasan, S. S. (2019). The availability, pricing, and affordability of essential diabetes medicines in 17 low-, middle-, and high-income countries. Front. Pharmacol. 10 (1375), 1375. doi:10.3389/fphar.2019.01375
Rajkumar, R. P. (2020). COVID-19 and mental health: a review of the existing literature. *Asian J Psychiatr* 52, 102066. doi:10.1016/j.ajp.2020.102066

Ramakrishnan, S., Zachariah, G., Gupta, K., Shikumvar Rao, J., Mohanan, P. P., Venugopal, K., et al. (2019). Prevalence of hypertension among Indian adults: results from the great India blood pressure survey. *Indian Heart J.* 71 (4), 309–313. doi:10.1016/j.ijhj.2019.09.012

Rathi, S., Ish, P., Kalantri, A., and Kalantri, S. (2020). Hydroxychloroquine prophylaxis for COVID-19 contacts in India. *The lancet infectious diseases.*

Ray, A., Najmi, A., Khandelwal, G., and Sadasivam, B. (2020). A cost variation analysis of drugs available in the indian market for the management of thromboembolic disorders. *Cureus* 12 (5), e7964. doi:10.7759/cureus.7964

Reddy, K. S. (2018). Health care reforms in India. *JAMA* 321 (24), 2477–2478. doi:10.1001/jama.2018.5284

Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., et al. (2020). Presenting characteristics, comorbidities, and outcomes among 57000 patients hospitalized with COVID-19 in the New York city area. *JAMA* 323 (20), 2052–2059. doi:10.1001/jama.2020.6775

Rosenberg, E. S., Duftor, E. M., Udo, T., Wilberscheid, L. A., Kumar, J., Tesoriero, J., et al. (2020). Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. *JAMA* 323 (24), 2493–2502. doi:10.1001/jama.2020.8630

Roy, A., Ghoshal, D., and Kalra, A. (2020). More patients than beds in Mumbai as India faces surge in virus cases. Available at: https://syrups.com/article/uk-health-coronavirus-india-medics-insignmore-patients-than-beds-in-mumbai-as-india-faces-surge-in-virus-cases

Saaqiq, S. (2020). Limited access to clean water among India’s poor spawns coronavirus concerns. Available at: https://news.yahoo.com/limited-access-clean-water-among-130525398.html.

SADC (2020). Statement by the SADC executive secretary, H.E Dr stergomena lawrence tax on covid-19 and gender based violence and domestic violence. Available at: https://www.sadc.int/news-events/news/statement-sadc-executive-secretary-he-dr-stergomena-lawrence-tax-covid-19-and-gender-based-violence-and-domestic-violence/

Salo, J. (2020). Nigeria reports poisonings from possible coronavirus drug chloroquine. Available at: https://nypost.com/2020/03/22/nigeria-reports-poisonings-from-possible-coronavirus-drug-chloroquine/ (Accessed March 22 2020).

Sanders, J. M., Monogee, M. L., Jodlowksi, T. Z., and Cuthrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA.*

Satheesh, G., Puthean, S., and Chaudhary, V. (2019). E-pharmacies in India: can we expand health insurance to individuals living below the poverty line. Available at: https://www.pnas.org/content/116/21/10578.

Srivastava, C. K., and Dhillon, G. S. (2020). The regulation of health care sector under the coronavirus disease 2019 (COVID-19) pandemic in the United States. *JAMA* 323 (24), 2524–2526. doi:10.1001/jama.2020.9184

Sonwalkar, P. (2020). Covid-19: Indians, non-whites in UK more at risk of death. Available at: https://www.hindustantimes.com/indians-abroad/covid-19-indians-non-whites-in-uk-more-at-risk-of-death/story-AdtVnxMxEl1IFaPW5W94O.html.

Sood, N., and Wagner, Z. (2020). JAMA health forum. India’s historic effort to expand health insurance to individuals living below the poverty line. Available at: https://jamanetwork.com/channels/health-forum/fullarticle/2763530.

Soon, J. M. Consumers’ awareness and trust toward food safety news on social media in Malaysia (2020). *J. Food Protect.* 83 (3), 452–459. doi:10.4315/0362-028X.JFP-19-415

Soumya, R., Devarashetty, V., Jayanthi, C. R., and Sushma, M. (2016). Drug dispensing practices at pharmacies in Bengaluru: a cross-sectional study. *Indian J Pharmacol.* 48 (4), 360–364. doi:10.1016/j.ipma.2016.02.004

Statista (2020). Fears and concerns arising from the coronavirus (COVID-19) across India in April 2020. Available at: https://www.statista.com/statistics/1111149/india-opinion-on-coronavirus-fears-and-concerns/ (Accessed April 26 2020).

Sunderkatta Abdulkader, R., Sinha, D. N., Jeyashree, K., Rath, R., Gupta, P. C., Kannan, S., et al. (2020). Trends in tobacco consumption in India 1987-2016: impact of the World health organization framework convention on tobacco control. *Int J Public Health* 64 (6), 841–851. doi:10.1007/s00038-019-01252-x

The Hindu (2020). Coronavirus India lockdown Day 159 updates. Available at: https://www.thehindu.com/news/national/coronavirus-india-lockdown-august-30-2020-live-updates/article32478249.ece/ (Accessed August 30 2020).

Tilangi, P., Desai, D., Khan, A., and Soneja, M. (2020). Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. *The Lancet Infectious diseases.*

Topp, S. Malaysia’s youngest hospital CEO on fighting coronavirus on the front lines. 4 April 2020. Available at URL: https://generationt.asia/leaders/malaysias-youngest-hospital-ceo-on-fighting-coronavirus-on-the-front-lines (Accessed April 4 2020).

Vaduganathan, M., van Meijgaard, J., Metha, M. R., Joseph, J., O’Donnell, C. J., and Warragh, H. J. (2020). Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States. *JAMA* 323 (24), 2524–2526. doi:10.1001/jama.2020.9184

Vardavas, C. I., and Nikitara, K. (2020). COVID-19 and smoking: a systematic review of the evidence. *Tob. Induc. Dis.* 18, 20.

Vijayakumar, G., Manghat, S., Vijayakumar, R., Simon, L., Scaria, L. M., Vijayakumar, A., et al. (2019). Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: results from a 10-year prospective cohort. *BMJ Public Health* 1 (1), 013001. doi:10.1136/bmjopen-2017-018020

Wang, Y., Zhang, D., and Du, G., (2020). Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. *Lancet* 395 (10236), 1569–1578. doi:10.1016/S0140-6736(20)31022-9

Weston, M. (2020). Coronavirus reaches Sudan, one of the countries least equipped to cope with it. Available at URL: https://mg.co.za/africa/2020-03-24-coronavirus-reaches-sudan-one-of-the-countries-least-equipped-to-cope-with-it/ (Accessed June 24 2020).

WHO (2018). Fact Sheet India 2018. Heart disease and stroke are the commonest ways by which tobacco kills people. Available at: https://apps.who.int/iris/bitstream/handle/10665/272672/wntd_2018_india_fs.pdf?sequence=1.

WHO (2020a). Coronavirus disease (COVID-19) Situation Report- 27 September 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200928-weekly-epi-update.pdf?sfvrsn=3534665_4 (Accessed October 1 2020).

WHO (2020b). Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Available at: https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations.

WHO (2020c). WHO discontinues hydroxychloroquine and lopinavir/ ritonavir treatment arms for COVID-19. Available at: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 (Accessed July 4 2020).

WHO India (2020a). Novel coronavirus disease (COVID-19) situation update report-1. Available at: https://www.who.int/docs/default-source/windria/india-situation-report-1.pdf?sfvrsn=5ca2a672_0.

WHO India (2020b). Novel coronavirus disease (COVID-19) situation update report-2. Available at: https://www.who.int/docs/default-source/windria/india-situation-report-2.pdf?sfvrsn=962294b_0.
WHO India (2020c). Novel coronavirus disease (COVID-19) situation update report - 6. Available at URL: https://www.who.int/docs/default-source/wrindia/situation-report/india-situation-report-660671da860b4d338b266c91265952977.pdf?sfvrsn=2f6c5c95_2.

WHO India (2020d). Novel coronavirus disease (COVID-19) situation update report - 7. Available at URL: https://www.who.int/docs/default-source/wrindia/situation-report/india-situation-report-7.pdf?sfvrsn=cf4a7312_2.

WHO India (2020e). Novel coronavirus disease (COVID-19) situation update report - 8. Available at URL: https://www.who.int/docs/default-source/wrindia/situation-report/india-situation-report-8bc9aca340f91408b9efbedb3917565fc.pdf?sfvrsn=5e0b8a43_2.

World Health Organisation (2020). Operational considerations for case management of COVID-19 in health facility and community: interim guidance. Available at URL: https://apps.who.int/iris/handle/10665/331492 (Accessed March 19 2020).

Wu, Z., and McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 323 (13), 1239–1242. doi:10.1001/jama.2020.2648

Yadav, P., Mehdiratta, A., Chalkidou, K., Rupani, S., and Reddy, K. (2020). India’s COVID-19 testing capacity must grow by a factor of 10: here’s how that can happen. Available at URL: https://www.cgdev.org/publication/indias-covid-19-testing-capacity-must-grow-factor-10-heres-how-can-happen.

Zhao, J., Yang, Y., Huang, H., Li, D., Gu, D., Lu, X., et al. (2020). Relationship between the ABO blood group and the COVID-19 susceptibility. MedRxiv preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.03.11.20031096v2.full.pdf (Accessed March 11 2020).

Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., et al. (2020). Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J. Infect. 81, e16–e25. doi:10.1016/j.jinf.2020.04.021

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a past co-authorship with one of the authors (BG).

Copyright © 2021 Haque, Kumar, Charan, Bhatt, Islam, Dutta, Abhayanand, Sharma, Sefah, Kurdi, Wale and Godman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
APPENDIX 1—QUESTIONNAIRE TO COMMUNITY PHARMACISTS IN INDIA.

The Questionnaire is designed to ascertain changes in the utilisation, prices and shortages of possible medicines and equipment to prevent and treat patients with COVID-19. You are free to participate or not, and confidentiality will be maintained.

Question 1: What is your location (City and region)?

Question 2: What changes in medicine purchasing patterns have you noticed in your pharmacy from the beginning of March, i.e. soon after the start of the pandemic but before major travel and other restrictions until the end of May, for antimalarials (hydroxychloroquine), antibiotics (e.g. azithromycin and co-amoxiclav), multivitamins including Vitamin C and analgesics [Please note - This is based on invoices where possible from prior to the beginning of March or other information sources; alternatively impressions (free text)]

Question 3: What changes in prices have you noticed in your pharmacy from the beginning of March until the end of May, for antimalarials (hydroxychloroquine), antibiotics (e.g. azithromycin and co-amoxiclav), multivitamins including Vitamin C and analgesics [Please note - This is based on invoices where possible from prior to the beginning of March or other information sources; alternatively impressions (free text)]

Question 4: Have there been any shortages for antimalarials (hydroxychloroquine), antibiotics (e.g. azithromycin and co-amoxiclav), multivitamins including Vitamin C and analgesics? If so, what is the extent of any shortages (free text)?

Question 5: What has been the changes in utilisation, prices and potential shortages for personal protection equipment (PPE) such as hand sanitisers and face masks in your pharmacy from the beginning of March until the end of May? [Please note - This is based on invoices where possible from prior to the beginning of March or other information sources; alternatively impressions (free text)]

Question 6: What suggestions do you have for the authorities in India to reduce misinformation regarding different management and treatment approaches for new pandemics as well as reduce inappropriate self-medication with antimicrobials (free text)?